This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Ranbaxy pushes court to dismiss Meijer's antitrust case

( December 8, 2015, 23:31 GMT | Official Statement) -- MLex Summary: Ranbaxy Laboratories and Sun Pharmaceutical filed a reply in support of their motion to dismiss claims that they conspired to delay the market entry of several generic drugs. The drugmakers say that Meijer’s opposition fails to counter the fact that their claims are predicated entirely on allegations of fraud on the Food and Drug Administration and therefore fall under the Food Drug and Cosmetic Act.   See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections